Abstract
We determined immune cross-recognition and the degree of Tat conservation in patients infected by local human immunodeficiency virus (HIV) type 1 strains. The data indicated a similar prevalence of total and epitope-specific anti-Tat IgG in 578 serum samples from HIV-infected Italian (n = 302), Ugandan (n = 139), and South African (n = 137) subjects, using the same B clade Tat protein that is being used in vaccine trials. In particular, anti-Tat antibodies were detected in 13.2%, 10.8%, and 13.9% of HIV-1-infected individuals from Italy, Uganda, and South Africa, respectively. Sequence analysis results indicated a high similarity of Tat from the different circulating viruses with BH-10 Tat, particularly in the 1-58 amino acid region, which contains most of the immunogenic epitopes. These data indicate an effective cross-recognition of a B-clade laboratory strain-derived Tat protein vaccine by individuals infected with different local viruses, owing to the high similarity of Tat epitopes.
| Original language | English |
|---|---|
| Pages (from-to) | 1171-1180 |
| Number of pages | 10 |
| Journal | Journal of Infectious Diseases |
| Volume | 188 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Oct 15 2003 |
Fingerprint
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
- Immunology
Cite this
Sequence Conservation and Antibody Cross-Recognition of Clade B Human Immunodeficiency Virus (HIV) Type 1 Tat Protein in HIV-1-Infected Italians, Ugandans, and South Africans. / Buttò, Stefano; Fiorelli, Valeria; Tripiciano, Antonella; Ruiz-Alvarez, Maria J.; Scoglio, Arianna; Ensoli, Fabrizio; Ciccozzi, Massimo; Collacchi, Barbara; Sabbatucci, Michela; Cafaro, Aurelio; Guzmán, Carlos A.; Borsetti, Alessandra; Caputo, Antonella; Vardas, Eftyhia; Colvin, Mark; Lukwiya, Matthew; Rezza, Giovanni; Ensoli, Barbara.
In: Journal of Infectious Diseases, Vol. 188, No. 8, 15.10.2003, p. 1171-1180.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Sequence Conservation and Antibody Cross-Recognition of Clade B Human Immunodeficiency Virus (HIV) Type 1 Tat Protein in HIV-1-Infected Italians, Ugandans, and South Africans
AU - Buttò, Stefano
AU - Fiorelli, Valeria
AU - Tripiciano, Antonella
AU - Ruiz-Alvarez, Maria J.
AU - Scoglio, Arianna
AU - Ensoli, Fabrizio
AU - Ciccozzi, Massimo
AU - Collacchi, Barbara
AU - Sabbatucci, Michela
AU - Cafaro, Aurelio
AU - Guzmán, Carlos A.
AU - Borsetti, Alessandra
AU - Caputo, Antonella
AU - Vardas, Eftyhia
AU - Colvin, Mark
AU - Lukwiya, Matthew
AU - Rezza, Giovanni
AU - Ensoli, Barbara
PY - 2003/10/15
Y1 - 2003/10/15
N2 - We determined immune cross-recognition and the degree of Tat conservation in patients infected by local human immunodeficiency virus (HIV) type 1 strains. The data indicated a similar prevalence of total and epitope-specific anti-Tat IgG in 578 serum samples from HIV-infected Italian (n = 302), Ugandan (n = 139), and South African (n = 137) subjects, using the same B clade Tat protein that is being used in vaccine trials. In particular, anti-Tat antibodies were detected in 13.2%, 10.8%, and 13.9% of HIV-1-infected individuals from Italy, Uganda, and South Africa, respectively. Sequence analysis results indicated a high similarity of Tat from the different circulating viruses with BH-10 Tat, particularly in the 1-58 amino acid region, which contains most of the immunogenic epitopes. These data indicate an effective cross-recognition of a B-clade laboratory strain-derived Tat protein vaccine by individuals infected with different local viruses, owing to the high similarity of Tat epitopes.
AB - We determined immune cross-recognition and the degree of Tat conservation in patients infected by local human immunodeficiency virus (HIV) type 1 strains. The data indicated a similar prevalence of total and epitope-specific anti-Tat IgG in 578 serum samples from HIV-infected Italian (n = 302), Ugandan (n = 139), and South African (n = 137) subjects, using the same B clade Tat protein that is being used in vaccine trials. In particular, anti-Tat antibodies were detected in 13.2%, 10.8%, and 13.9% of HIV-1-infected individuals from Italy, Uganda, and South Africa, respectively. Sequence analysis results indicated a high similarity of Tat from the different circulating viruses with BH-10 Tat, particularly in the 1-58 amino acid region, which contains most of the immunogenic epitopes. These data indicate an effective cross-recognition of a B-clade laboratory strain-derived Tat protein vaccine by individuals infected with different local viruses, owing to the high similarity of Tat epitopes.
UR - http://www.scopus.com/inward/record.url?scp=0242364649&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0242364649&partnerID=8YFLogxK
U2 - 10.1086/378412
DO - 10.1086/378412
M3 - Article
VL - 188
SP - 1171
EP - 1180
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 8
ER -